TaiMed Biologics Inc. (4147.TWO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chin-Ming Chang Ph.D. | President & CEO | -- | -- | -- |
| Dr. David D. Ho M.D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director | -- | -- | 1953 |
| Dr. Ing-Wen Tsai Ph.D. | Co-Founder | -- | -- | -- |
| Dr. Lan-Bo Chen Ph.D. | Co-Founder | -- | -- | -- |
| Mr. Jack Chen CPA | CFO & Chief of Corporate Governance | -- | -- | -- |
| Chen Yicheng | Accounting Supervisor | -- | -- | -- |
TaiMed Biologics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment. In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.
Corporate Governance
Upcoming Events
August 6, 2025 at 10:59 AM UTC - August 11, 2025 at 12:00 PM UTC
TaiMed Biologics Inc. Earnings Date
Recent Events
Recent Events Information Not Available